These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis. Lee J; Cummins G; Okamoto L Am J Manag Care; 2001 May; 7(4 Suppl):S103-12. PubMed ID: 11392821 [TBL] [Abstract][Full Text] [Related]
12. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. Liao E; Leahy M; Cummins G Am J Manag Care; 2001 Oct; 7(15 Suppl):S459-68. PubMed ID: 11680261 [TBL] [Abstract][Full Text] [Related]
13. FDA announces plan to halt marketing of terfenadine. Am J Health Syst Pharm; 1997 Feb; 54(4):342. PubMed ID: 9043551 [No Abstract] [Full Text] [Related]
14. [Long QT interval. Interaction of terfenadine and itraconazole]. Rufke C; Nieber K Med Monatsschr Pharm; 2006 Jan; 29(1):22-4. PubMed ID: 16463550 [No Abstract] [Full Text] [Related]
15. [Therapy of allergic rhinitis: recommendations of US-American experts. Critical evaluation of 1st generation antihistaminics]. MMW Fortschr Med; 1999 Nov; 141(44):46, 48. PubMed ID: 10912146 [No Abstract] [Full Text] [Related]
16. Study protocol on azelastine. Kelso JM Ann Allergy Asthma Immunol; 1997 Feb; 78(2):244. PubMed ID: 9048537 [No Abstract] [Full Text] [Related]
17. Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine. Stone BM; Turner C; Mills SL; Nicholson AN Int Arch Allergy Immunol; 1999; 118(2-4):338. PubMed ID: 10224436 [No Abstract] [Full Text] [Related]